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Summary
Background.  —  Heart  rate  is  a  major  determinant  of  myocardial  oxygen  demand;  in  ST-segment
elevation myocardial  infarction  (STEMI),  patients  treated  with  primary  percutaneous  inter-infarction;
Left  ventricular
remodelling;
Magnetic  resonance
imaging
vention (PPCI),  heart  rate  at  discharge  correlates  with  mortality.  Ivabradine  is  a  pure  heart
rate-reducing  agent  that  has  no  effect  on  blood  pressure  and  contractility,  and  can  reverse  left
ventricular  (LV)  remodelling  in  patients  with  heart  failure.
Aims. —  To  evaluate  whether  ivabradine,  when  added  to  current  guideline-based  therapy,
improves LV  remodelling  in  STEMI  patients  treated  with  PPCI.
Abbreviations: AMI, acute myocardial infarction; b.p.m., beats per minute; CMR, cardiovascular magnetic resonance imaging; HR, heart
rate; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ven-
tricular end-systolic volume; PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIMI,
Thrombolysis In Myocardial Infarction.
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Methods.  —  This  paired-cohort  study  included  124  patients  between  June  2011  and  July  2012.
Ivabradine  (5  mg  twice  daily)  was  given  promptly  after  PPCI,  along  with  beta-blockers,  to  obtain
a heart  rate  <  60  beats  per  minute  (ivabradine  group).  This  group  was  matched  with  STEMI
patients treated  in  line  with  current  guidelines,  including  beta-blockers  (bisoprolol),  according
to age,  sex,  infarct-related  coronary  artery,  ischaemia  time  and  infarct  size  determined  by
initial cardiac  magnetic  resonance  imaging  (CMR)  (control  group).  Statistical  analyses  were
performed according  to  an  intention-to-continue  treatment  principle.  CMR  data  at  3  months
were available  for  122  patients.
Results.  —  Heart  rate  was  lower  in  the  ivabradine  group  than  in  the  control  group  during  the
initial CMR  (P  =  0.02)  and  the  follow-up  CMR  (P  =  0.006).  At  the  follow-up  CMR,  there  was  a
smaller increase  in  LV  end-diastolic  volume  index  in  the  ivabradine  group  than  in  the  control
group (P  =  0.04).  LV  end-systolic  volume  index  remained  unchanged  in  the  ivabradine  group,  but
increased in  the  control  group  (P  =  0.01).  There  was  a  signiﬁcant  improvement  in  LV  ejection
fraction in  the  ivabradine  group  compared  with  in  the  control  group  (P  =  0.04).
Conclusions.  —  In  successfully  reperfused  STEMI  patients,  ivabradine  may  improve  LV  remod-
elling when  added  to  current  guideline-based  therapy.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  fréquence  cardiaque  est  un  déterminant  majeur  de  la  demande  en  oxygène  du
myocarde.  Chez  les  patients,  ayant  présenté  un  syndrome  coronarien  aigu  avec  sus-décalage  du
segment  ST,  revascularisés  par  une  angioplastie  primaire  percutanée,  la  fréquence  cardiaque  à
la sortie  de  l’hôpital  est  corrélée  à  la  mortalité.  L’ivabradine  est  un  pur  agent  bradycardisant
et n’a  pas  d’effet  sur  la  pression  artérielle  et  la  contractilité  myocardique  ;  l’ivabradine  peut
inverser  le  remodelage  ventriculaire  gauche  chez  le  patients  atteints  d’insufﬁsance  cardiaque.
Objectifs.  —  Évaluer  si  l’ivabradine,  ajouté  aux  traitements  habituellement  recommandés,
améliore  le  remodelage  ventriculaire  gauche  chez  des  patients  ayant  présenté  un  syndrome
coronarien aigu  avec  sus-décalage  du  segment  ST  qui  ont  été  revascularisés  par  une  angioplastie
primaire  percutanée.
Méthodes.  —  Cette  étude  de  cohorte  appariée  a  inclus  124  patients  entre  juin  2011  et  juillet
2012. L’ivabradine  à  la  dose  de  5  mg  deux  fois  par  jour  a  été  administrée  rapidement  après
l’angioplastie  primaire  percutanée  de  manière  concomitante  aux  bêta-bloquants  pour  obtenir
une fréquence  cardiaque  inférieure  à  60/min  (le  groupe  ivabradine).  Ce  groupe  a  été  apparié
avec d’autres  patients  ayant  présenté  un  syndrome  coronarien  aigu  avec  sus-décalage  du  seg-
ment ST,  traités  selon  les  recommandations  incluant  des  bêta-bloquants  (le  groupe  témoin).  Les
2 groupes  étaient  appariés  selon  l’âge,  le  sexe,  l’artère  responsable  de  l’infarctus,  le  temps
d’ischémie  et  la  taille  de  l’infarctus  déterminé  par  l’IRM  initiale.  L’analyse  statistique  était
réalisée en  intention  de  continuer  le  traitement.  Les  données  IRM  étaient  disponibles  pour
122 patients.
Résultats.  —  La  fréquence  cardiaque  était  inférieure  dans  le  groupe  ivabradine  par  rapport
au groupe  témoin  lors  de  l’IRM  initiale  (p  =  0,02)  et  de  l’IRM  de  contrôle  (p  =  0,006).  Lors  du
suivi IRM,  un  traitement  par  ivabradine  était  associé  à  une  moindre  augmentation  du  vol-
ume télédiastolique  ventriculaire  gauche  indexé  que  dans  le  groupe  témoin  (p  =  0,04).  Dans
le groupe  ivabradine,  le  volume  télésystolique  ventriculaire  gauche  indexé  était  inchangé  alors
qu’il augmentait  dans  le  groupe  témoin  (p  =  0,01).  Il  y  avait  une  amélioration  signiﬁcative  de
la fraction  d’éjection  ventriculaire  gauche  dans  le  groupe  ivabradine  par  rapport  au  groupe
témoin (p  =  0,04).
Conclusion.  —  Chez  les  patients  reperfusés  avec  succès  après  un  infarctus  du  myocarde,
l’ivabradine  associé  aux  traitements  habituellement  recommandés  peut  améliorer  le  remod-
elage ventriculaire  gauche.
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ackground
cute  myocardial  infarction  (AMI)  induces  scar  formation
nd  changes  in  the  surviving  myocardium,  designated  as
ost-AMI  ventricular  remodelling  [1].  Adverse  left  ventricu-
ar  (LV)  remodelling,  deﬁned  as  an  increase  in  LV  end-systolic
m
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es  droits  réservés.
olume  (LVESV)  is  associated  with  progression  to  heart
ailure  and  poor  outcome.  The  therapeutic  effects  of  beta-
lockade,  angiotensin-converting  enzyme  inhibition  and
ineralocorticoid  receptor  antagonist  (MRA)  inhibition  have
een  linked  to  their  beneﬁcial  effects  on  cardiac  remod-
lling  [2—4].  Thus,  oral  treatment  with  beta-blockers  should
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b.p.m.  during  hospitalization.  Other  therapies,  including
angiotensin-converting  enzyme  inhibitors,  angiotensin  II
receptor  blockers  and  MRAs  if  considered  appropriate,  were
Figure 1. All patients presenting with ST-segment elevation
myocardial infarction underwent primary percutaneous coronary
intervention (PPCI). At admission to the intensive care unit (ICU),
between 1 and 3 hours after angioplasty, ivabradine 5 mg  was given
orally, twice daily. A concomitant beta-blocker (e.g. bisoprolol) wasIvabradine  and  left  ventricular  remodelling  after  STEMI  
be  considered  during  hospital  stay  and  continued  thereafter
in  all  patients  with  ST-segment  elevation  myocardial  infarc-
tion  (STEMI)  [5].  Heart  rate  (HR)  is  a  major  determinant  of
myocardial  oxygen  demand.  Furthermore,  in  STEMI  patients
treated  with  primary  percutaneous  intervention  (PPCI),  HR
at  discharge  has  been  found  to  correlate  with  mortality  [6].
Ivabradine  is  a  pure  HR  reducing  agent  that  has  no  effect
on  blood  pressure  and  contractility.  The  results  of  the  Sys-
tolic  Heart  failure  treatment  with  the  If inhibitor  ivabradine
Trial  (SHIFT)  showed  that  an  HR  decrease  with  ivabradine
reversed  LV  remodelling  in  patients  with  heart  failure  [7].
In  the  same  way,  ivabradine  improved  the  LV  pressure-
volume  relationship,  decreased  interstitial  collagen  content
and  increased  capillary  density  in  young  adult  rats  with  AMI
and  congestive  heart  failure  [8].  Only  one  trial  has  inves-
tigated  the  effects  of  ivabradine  versus  beta-blockers  in
early  phases  of  anterior  STEMI  with  impaired  LV  function
treated  with  PPCI  [9].  In  this  study,  at  2-month  follow-up,
patients  treated  with  ivabradine  had  a  signiﬁcant  increase
in  LV  ejection  fraction  (LVEF),  with  concomitant  reduction
in  LVESV  and  LV  end-diastolic  volume  (LVEDV).  However,  to
our  best  knowledge,  no  study  has  evaluated  the  additional
value  of  ivabradine  in  STEMI  patients  treated  with  success-
ful  PPCI  and  optimal  medical  therapy.  Therefore,  our  study
was  designed  speciﬁcally  to  evaluate  whether  ivabradine
improves  LV  remodelling  after  AMI  when  added  to  current
guideline-based  therapy,  including  beta-blockers,  in  STEMI
patients  treated  with  successful  PPCI.
Methods
We  decided  to  conduct  a  non-randomized  study  because  we
felt  we  did  not  have  enough  strong  preliminary  scientiﬁc
data  on  the  use  of  ivabradine  in  humans  during  the  acute
phase  of  myocardial  infarction.  However,  in  view  of  the
experimental  data,  we  wanted  to  conduct  a  pilot  study  to
assess  the  feasibility  and  impact  on  LV  remodelling  of  adding
ivabradine  to  standard  pharmacological  therapy  following
PPCI  in  patients  presenting  with  STEMI.
Patients
This  paired-cohort  study  was  approved  by  the  ethics  com-
mittee  of  our  institution  and  all  patients  gave  their
written  informed  consent  before  inclusion.  Between  June
2011  and  July  2012,  all  consecutive  patients  presenting
with  a  STEMI  were  considered  eligible  for  participation.
Among  them,  two  matched  groups  were  formed:  the
ivabradine  group  and  the  control  group.  Inclusion  crite-
ria  were:  the  presence  of  an  inaugural  STEMI,  deﬁned
by  prolonged  chest  pain,  troponin  T  concentration  higher
than  twice  the  upper  limit  (>  0.01  ng/mL)  and  electrocar-
diogram  changes  on  at  least  two  contiguous  leads  with
pathological  Q  waves  (>  0.04  seconds)  and/or  persisting  ST-
segment  elevation  (>  0.1  mV);  and  successful  reperfusion
(Thrombolysis  in  Myocardial  Infarction  [TIMI]  ﬂow  grade
3  in  the  infarct-related  artery).  Exclusion  criteria  were:
unsuccessful  myocardial  reperfusion  (TIMI  ﬂow  grade  ≤  2);
thrombolysis;  haemodynamic  instability;  atrial  arrhythmia;
HR  <  70  beats  per  minute  (b.p.m.)  1  hour  after  coronary
angioplasty;  and  contraindications  to  cardiac  magnetic
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esonance  imaging  (CMR).  The  ivabradine  group  was
atched  with  a  control  group  of  STEMI  patients  according
o  age,  sex,  infarct-related  coronary  artery,  ischaemia  time
nd  infarct  size  determined  by  initial  CMR.
mergency care and percutaneous procedure
uring  transport  for  percutaneous  coronary  intervention
PCI),  all  patients  received  intravenous  low-molecular-
eight  heparin  (enoxaparin;  0.5  mg/kg),  intravenous  aspirin
≥  250  mg)  and  loading  doses  of  clopidogrel  (≥  600  mg)  or
rasugrel  (≥  60  mg).  All  patients  underwent  PPCI  with  bare-
etal  and/or  drug-eluting  stent  implantation  in  the  culprit
rtery.  A  glycoprotein  IIb/IIIa  inhibitor  (abxicimab)  was
dministered  during  the  procedure,  at  the  discretion  of  the
perator.  Thrombus  aspiration  before  stent  implantation  of
he  infarct-related  coronary  artery  was  performed,  accord-
ng  to  the  guidelines  [10]. Coronary  ﬂow  before  and  after
evascularization  was  graded  according  to  the  TIMI  study
roup  classiﬁcation  [11]  by  two  blinded  observers  (25  and  10
ears  of  experience  in  coronary  angiography,  respectively).
 successful  procedure  was  deﬁned  when  both  TIMI  grade  3
nd  residual  diameter  stenosis  <  30%  were  obtained.
tudy plan and treatments
atients  were  assigned  to  a treatment  group,  according
o  the  decision  (free  choice)  of  the  cardiologist  in  charge
t  admission  to  the  intensive  care  unit  after  the  coronary
ngioplasty.  The  study  plan  is  presented  in  Fig.  1.  Between
 and  3  hours  after  angioplasty,  patients  in  the  ivabra-
ine  group  and  presenting  with  HR  ≥  70  b.p.m.  received  a
 mg  test  dose  of  ivabradine  to  evaluate  their  tolerance;
vabradine  was  then  given  orally  at  the  5  mg  dose,  twice
aily.  A  concomitant  beta-blocker  (bisoprolol)  was  given
nd  uptitrated  to  10  mg  to  reach  the  target  HR  i.e.  <  60iven and, if possible, uptitrated to 10 mg to reach the target heart
ate (i.e. < 60 beats per minute [b.p.m.]) during hospitalization. Ini-
ial cardiac magnetic resonance imaging (CMR) was then performed.
uring follow-up, the patient underwent CMR at 3 months.
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ptimized  in  accordance  with  contemporary  guidelines.  If
he  resting  HR  was  <  50  b.p.m.  or  the  patient  experienced
ymptoms  related  to  bradycardia,  the  dose  of  ivabradine
as  reduced  to  2.5  mg,  twice  daily.  LV  volume  and  mass,
VEF,  myocardial  wall  thickness  in  infarct  and  remote  non-
nfarcted  myocardium  and  infarct  size  were  assessed  in  all
atients  by  performing  CMR  during  hospitalization.  The  con-
rol  group  included  patients  treated  according  to  current
uidelines  [5],  including  beta-blockers  (bisoprolol  in  our
entre),  to  obtain  a  HR  <  60  b.p.m.  at  discharge.  In  our  insti-
ution,  all  these  patients  were  evaluated  using  initial  CMR  a
ew  days  after  AMI  and  follow-up  CMR  at  3  months.
MR protocol and analysis
MR  studies  were  performed  on  a  1.5  T  clinical  scanner
quipped  with  a  32-channel  cardiac  coil  (Avanto;  Siemens
edical  Solutions,  Forchheim,  Germany).  Cine  imaging  was
erformed  to  acquire  a  stack  of  short-axis  slices  covering
he  whole  of  the  left  ventricle  (LV)  from  base  to  apex,
sing  an  electrocardiogram-gated  balanced  steady-state
ree-precession  breath-hold  sequence  with  the  following
arameters:  repetition  time/echo  time  20—30/1.4  ms;  ﬂip
ngle  60◦;  slice  thickness  6  mm;  pixel  size  1.6  ×  1.6  to
.8  ×  1.8  mm;  20  frames  per  cardiac  cycle.  Late  gadolinium-
nhanced  imaging  was  performed  to  acquire  a  stack  of
hort-axis  slices  covering  the  whole  LV  from  base  to  apex.
cquisition  was  initiated  15  minutes  after  the  injection
f  0.2  mmol/kg  gadoterate  meglumine  (Dotarem;  Guerbet,
ulnay-Sous-Bois,  France)  using  an  inversion-recovery-
repared  three-dimensional  turbo  fast  low-angle  shot
reath-hold  sequence  with  the  following  parameters:  TR/TE
00/1.4  ms;  ﬂip  angle  10◦;  slice  thickness  6  mm;  pixel  size
.8  ×  1.4  mm.  Inversion  time  was  optimized  on  a  previously-
cquired  TI  scouting  sequence  [12].  Data  were  exported  to
 separate  workstation  for  analysis  using  a  commercially
vailable  software  package  (MASS  version  7.0;  Medis  Medical
maging  Systems,  Leiden,  The  Netherlands).  Image  segmen-
ation  was  performed  by  two  observers  (with  12  and  2  years
f  experience  in  CMR,  respectively)  blinded  to  clinical  data,
ncluding  the  treatment  with  ivabradine.  Endocardial  and
picardial  contours  were  segmented  on  end-diastolic  and
nd-systolic  frames  at  each  short-axis  location.  LV  trabecu-
ae  and  papillary  muscles  were  included  in  the  ventricular
olume  [13].  LVEDV  and  LVESV  were  computed  in  millilitres
sing  the  modiﬁed  Simpson’s  rule  [14]  and  were  used  to  cal-
ulate  LVEF,  expressed  as  a  percentage.  Adverse  LV  remod-
lling  was  deﬁned  as  an  increase  in  LVESV  ≥  15%  at  follow-up
15].  LV  mass  (in  grams)  was  calculated  from  the  total
olume  of  myocardium  at  end  diastole  multiplied  by  the
yocardial  density  of  1.05  g/mL.  LV  volumes  were  indexed
o  body  surface  area.  Delayed-enhanced  short-axis  images
ere  segmented  at  a  different  time  point  by  the  same
bservers.  Endo-  and  epicardial  contours  were  manually
raced  and  myocardial  scar  was  automatically  segmented,
ith  a  threshold  set  at  50%  maximal  signal  intensity  [16].
tatistical analysisontinuous  data  are  expressed  as  means  ±  standard  devi-
tions  when  they  followed  a  normal  distribution  and
s  medians  (interquartile  ranges)  when  they  did  not.
n
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ategorical  data  are  expressed  as  absolute  values  (per-
entages).  Statistical  analyses  were  performed  according
o  an  intention-to-continue  treatment  principle.  When
ollow-up  CMR  data  were  missing,  they  were  replaced
y  values  reﬂecting:  increased  LVEDV  and  LVESV  of  20%;
ecreased  myocardial  wall  thickness  in  infarct  myocardium
nd  decreased  LV  mass  of  10%.  Clinical  and  paraclinical  char-
cteristics  were  compared  between  the  two  groups  using
wo-sampled  t  tests  (or  their  non-parametric  equivalents,
.e.  the  Mann-Whitney  test  and  the  signed-rank  Wilcoxon’s
est).  Two-sampled  t  tests  were  also  used  to  compare
hanges  in  continuous  variables  from  initial  CMR  to  follow-
p  CMR  between  the  two  groups.  Comparison  of  categorical
ariables  was  achieved  using  the  chi-square  test  or  Fisher’s
xact  test.  All  statistics  were  calculated  using  NCSS  and  PASS
oftware  (NCSS  2001;  NCSS  Statistical  Software,  Kaysville,
tah).  P  values  <  0.05  were  considered  signiﬁcant.
esults
opulation
f  456  STEMI  patients  screened,  170  patients  satisﬁed  all  the
nclusion  and  exclusion  criteria.  These  patients,  according
o  the  decision  of  the  cardiologist  in  charge,  were  assigned
o  either  the  ivabradine  group  or  the  control  group.  Among
hem,  124  Caucasian  patients  were  matched,  to  form  two
roups  (Fig.  2).  The  ﬁnal  analysis  included  124  patients
hose  characteristics  are  reported  Table  1.
vabradine group
he  ﬁrst  examination  was  carried  out  6.1  ±  1.9  days  after
MI.  Five  patients  had  to  stop  ivabradine  treatment.  Six
ays  after  the  AMI,  one  patient  developed  acute  cholecysti-
is  requiring  surgery.  Seven  days  after  AMI,  one  patient  had
 syncope  secondary  to  torsades  de  pointes  and  this  patient
ad  bradycardia  (i.e.  HR  <  50  b.p.m.)  associated  with  severe
ypokalemia  (2.7  mmol/L).  During  the  time  between  the  ini-
ial  and  follow-up  CMRs,  three  patients  presented  excessive
radycardia  (i.e.  HR  <  45  b.p.m.)  that  required  cessation  of
vabradine  treatment.  For  three  patients,  the  dose  of  ivabra-
ine  was  reduced  to  2.5  mg,  twice  daily;  among  them,  one
atient  did  not  undergo  follow-up  CMR.  Another  patient
as  unable  to  complete  the  follow-up  CMR  because  he  had
ained  8.2  kg  in  body  weight.
ontrol group
he  ﬁrst  examination  was  carried  out  6.3  ±  1.7  days  after
he  AMI.  No  adverse  events  were  noticed  in  this  group.
s  reported  in  Table  1,  there  were  no  signiﬁcant  differ-
nces  between  the  ivabradine  and  control  groups  in  terms  of
o-morbidities,  ischaemia  time,  coronary  angiography  char-
cteristics  at  admission  and  medical  treatment  at  3 months,
ncluding  beta-blocker  dosage.  At  6  days,  the  infarct  size  in
he  control  group  was  15.6  ±  6.8%  of  the  LV  mass  and  did
ot  differ  from  the  infarct  size  in  the  ivabradine  group,
hich  was  16.3  ±  7.5%  of  the  LV  mass  (P  =  0.56).  LVEF  was
6.4  ±  9.1%  and  57.9  ±  9.8%  in  the  control  and  ivabradine
roups,  respectively  (P  =  0.35).
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fFigure 2. Flow chart for inclusion of patients in the study. CMR: c
elevation myocardial infarction; TIMI: thrombolysis in myocardial in
Changes in HR  in the two groups
HR  showed  a  signiﬁcant  reduction  between  1  hour  after
angioplasty  and  3  months  of  treatment  in  both  groups  (from
76.7  ±  7.0  to  54.7  ±  5.8  b.p.m.  in  the  ivabradine  group  and
from  76.0  ±  6.2  to  57.6  ±  6.5  b.p.m.  in  the  control  group;
P  <  0.001)  (Table  2).  Furthermore,  HR  was  lower  in  the
ivabradine  group  than  in  the  control  group  during  initial  CMR
(56.2  ±  4.8  b.p.m.  vs  58.8  ±  6.0  b.p.m.;  P  =  0.02);  this  differ-
ence  increased  during  follow-up  CMR  (54.7  ±  5.8  b.p.m.  vs
57.6  ±  6.5  b.p.m.;  P  =  0.006).
Changes in LV volumes and function between
initial and follow-up CMRAt  the  initial  CMR,  there  were  no  signiﬁcant  differences  in
LVEDV  index,  LVESV  index  and  LVEF  between  the  two  groups
(P  =  0.96,  P  =  0.43  and  P  =  0.35,  respectively).  Late  microvas-
cular  obstruction  on  late  gadolinium-enhanced  imaging  was
w
c
L
ic magnetic resonance imaging; HR: heart rate; STEMI: ST-segment
ion.
resent  in  29  patients  (46.8%)  in  the  ivabradine  group;  27
atients  (43.5%)  in  the  control  group  also  demonstrated  late
icrovascular  obstruction  (P  =  0.59).  Follow-up  CMR  data
ere  missing  for  two  patients  in  the  ivabradine  group.  At
he  follow-up  CMR,  the  increase  in  LVDEV  index  was  smaller
n  the  ivabradine  group  than  in  the  control  group  (P  =  0.04)
Table  3).  The  LVESV  index  remained  globally  unchanged
n  the  ivabradine  group,  whereas  it  increased  in  the  con-
rol  group  (P  =  0.01).  Adverse  LV  remodelling  occurred  in
4  (21.8%)  patients  in  the  ivabradine  group  and  20  (31.3%)
atients  in  the  control  group  (P  =  0.23).  Regarding  LVEF
hanges,  there  was  a  signiﬁcant  (P  =  0.04)  improvement  in
he  ivabradine  group  compared  with  in  the  control  group.
urthermore,  there  was  an  inverse  relationship  (r  =  —0.19,
 =  0.04)  between  the  change  in  HR  (between  initial  and
ollow-up  CMR)  and  the  change  in  LVEF.  In  contrast,  there
as  no  signiﬁcant  relationship  between  changes  in  HR  and
hanges  in  LV  volumes  for  all  patients  (r  =  0.10,  P  = 0.24  for
VEDV  index  variation  [%]  and  r  =  0.14,  P  = 0.10  for  LVESV
ndex  variation  [%]).
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Table  1  Study  population  baseline  characteristics.
Ivabradine
(n  =  62)
Control
(n =  62)
P
Mean  age  (years)  56.7  ±  11.7  58.2  ±  10.5  0.45
Men  56  (90.3)  55  (88.7)  0.77
Family  history  of  premature  heart  disease 25  (40.3) 28  (45.2)  0.59
Hypertensiona 23  (37.1) 26  (41.9) 0.58
Smokers  43  (69.3) 42  (67.7) 0.85
Hyperlipidaemiab 42  (67.7) 40  (64.5) 0.45
Body  mass  index  (kg/m2) 26.7  (24.5—29.0) 26.2  (23.4—28.4) 0.23
Diabetes  mellitus  14  (22.6)  12  (19.3)  0.66
Ischaemia  time  (minutes)  294  ±  182  291  ±  169  0.79
Coronary  angiography
Infarct-related  artery  0.81
LAD  29  (46.8)  27  (43.5)
LCx  12  (19.4)  15  (24.2)
RCA  21  (33.8)  20  (32.3)
Single-vessel  diseasec 22  (35.5)  23  (37.1)  0.91
Double-vessel  diseasec 23  (37.1)  23  (37.1)  1.0
Triple-vessel  diseasec 17  (27.4)  16  (25.8)  0.73
TIMI  ﬂow  grade  ≥  2  before  PCI  16  (25.8)  12  (19.4)  0.39
Medication  at  follow-up  (3  months)
Aspirin  62  (100)  62  (100)  1.0
ADP  receptor  inhibitors  62  (100)  62  (100)  1.0
ACEi  or  A2  receptor  blockers  61  (98.4)  59  (95.2)  0.31
MRA  9  (14.5)  10  (16.1)  0.80
Beta-blocker  62  (100)  62  (100)  1.0
Beta-blocker  dosage  (mg/day)d 4.0  (2.5—5)  4.2  (2.5—5)  0.84
Statins  62  (100)  62  (100)  1.0
Data are expressed as mean ± standard deviation, number (%) or median (interquartile range). A2: angiotensin II receptor blocker; ACEi:
angiotensin-converting enzyme inhibitor; ADP: adenosine diphosphate; LAD: left anterior descending artery; LCx: left circumﬂex artery;
MRA: mineralocorticoid receptor antagonist; PCI: percutaneous coronary intervention; RCA: right coronary artery; TIMI: Thrombolysis
In Myocardial Infarction.
a Hypertension was deﬁned as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.
b Hyperlipidaemia was deﬁned as total cholesterol > 6.5 mmol/L, low-density lipoprotein cholesterol > 4.0 mmol/L or high-density lipopro-
tein cholesterol < 1.2 mmol/L.
c A lumen reduction of > 50% diameter stenosis was considered signiﬁcant.
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td Bisoprolol, the beta-blocker of preference, according to the loc
hanges in regional wall thickness between
nitial and follow-up CMR
e  found  no  signiﬁcant  difference  in  global  LV  mass  index
etween  the  two  groups  of  patients  at  initial  CMR  (P  =  0.15)
Table  3).  At  follow-up  CMR,  there  was  a  signiﬁcant  (P  =  0.02)
rend  towards  a  reduction  in  LV  mass  index  in  the  control
roup.
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Table  2  Changes  in  heart  rate  at  baseline,  day  1  and  during  i
Heart  rate  (beats  per  minute)  Ivabradine
(n  =  62)
1  hour  after  angioplasty  76.7  ±  7.0  
Day  1  65.9  ±  5.5  
Initial  CMR  56.2  ±  4.8  
Follow-up  CMR  54.7  ±  5.8  
Data are expressed as mean ± standard deviation. CMR: cardiac magnestitutional protocol.
In  the  infarcted  myocardium,  there  was  a  non-signiﬁcant
P  =  0.31)  trend  toward  less  reduction  of  end-diastolic
all  thickness  in  the  ivabradine  group  (from  7.6  ±  1.4
o  7.1  ±  1.5  mm)  compared  with  the  control  group  (from
.7  ±  1.1  to  6.8  ±  1.4  mm).  Furthermore,  there  was  a
on-signiﬁcant  (P  =  0.40)  trend  toward  less  reduction  of
nd-systolic  wall  thickness  in  the  ivabradine  group  (from
.1  ±  2.2  to  8.4  ±  2.4  mm)  compared  with  the  control
nitial  and  follow-up  cardiac  magnetic  resonance  imaging.
Control
(n  =  62)
P
76.0  ±  6.2  0.79
64.4  ±  7.7  0.21
58.8  ±  6.0  0.02
57.6  ±  6.5  0.006
tic resonance imaging.
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Table  3  Findings  from  initial  and  follow-up  cardiac  magnetic  resonance  imaging.
Ivabradine  group  Control  group  Pa
Baselineb 3  monthsb Variation  (%)  Baselineb 3  monthsb Variation  (%)
LVEDV  index  (mL/m2)  72.5  ±  14.6  75.0  ±  18.5  3.3  ±  12.9  72.3  ±  16.1  78.5  ±  18.0  9.9  ±  20.6  0.04
LVESV  index  (mL/m2)  31.0  ±  11.1  31.0  ±  14.4  —0.7  ±  21.7  32.0  ±  10.4  35.3  ±  14.3  10.5  ±  29.5  0.01
LVEF  (%) 57.9  ±  9.8  60.0  ±  10.4  4.0  ±  9.9  56.4  ±  9.1  56.5  ±  10.6  0.1  ±  12.7  0.04
Infarct  size  (g) 24.4  ±  13.0 17.0  ±  8.7 —27.4 ±  15.6 24.4  ±  12.5  16.3  ±  8.4  —30.0  ±  16.6  0.48
Infarct  size  (%  of  LV  mass) 16.3  ±  7.5 11.5  ±  5.1 —26.4 ±  13.5 15.6  ±  6.8 11.2  ±  5.1  —26.4  ±  16.5  0.97
LV  mass  index  (g/m2) 79.2  ±  15.8 77.3  ±  14.0 —1.6 ±  7.8 82.3  ±  12.9 77.7  ±  13.7 —5.4 ±  8.5 0.02
Data are expressed as mean ± standard deviation. LV: left ventricular; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular
ejection fraction; LVESV: left ventricular end-diastolic volume.
a Compares the magnitude of difference in the ivabradine group with the magnitude of difference in the control group.
b Baseline and 3 months correspond to initial and control cardiac magnetic resonance imaging, respectively.
Table  4  Left  ventricular  wall  thickness  in  the  infarcted
and  remote  myocardium  at  baseline  and  follow-up.
Ivabradine
(n  =  62)
Control
(n =  62)
Infarcted  myocardium  (mm)
Baselinea
EDWT  7.6  ±  1.4  7.7  ±  1.1
ESWT  9.1  ±  2.2  9.2  ±  1.9
3  monthsa
EDWT  7.1  ±  1.5  6.8  ±  1.4
ESWT  8.4  ±  2.4  8.0  ±  2.3
Remote  myocardium  (mm)
Baselinea
EDWT  7.9  ±  0.7  8.0  ±  0.8
ESWT  13.3  ±  1.3  13.6  ±  1.3
3  monthsa
EDWT  8.4  ±  0.8  8.5  ±  1.1
ESWT  13.9  ±  1.3  13.9  ±  1.4
Data are expressed as mean ± standard deviation. EDWT: end-
diastolic wall thickness; ESWT: end-systolic wall thickness.
There were no statistical differences between groups as
assessed by two-way analysis of variance (P = not signiﬁcant).
a Baseline and 3 months correspond to initial and control cardiac
magnetic resonance imaging, respectively.
i
g
a
D
T
a
i
c
r
c
t
t
A
g
r
a
a
i
c
h
i
a
w
r
b
(
e
p
e
o
d
t
i
w
neously  improves  oxygen  supply  by  prolonging  diastole,group  (from  9.2  ±  1.9  to  8.0  ±  2.3  mm)  (Table  4).  In  the
myocardium  remote  to  the  infarct  there  was  no  signiﬁcant
effect  of  ivabradine  on  end-diastolic  or  end-systolic  wall
thickness  at  initial  and  follow-up  CMR.  In  both  groups,  there
was  a  trend  towards  a  moderate  increase  in  end-diastolic
and  end-systolic  wall  thickness  between  initial  and  follow-up
CMR.
Changes in infarct size between initial and
control CMRIn  both  groups,  infarct  size  was  signiﬁcantly  reduced  at
3  months  compared  with  baseline  (P  <  0.001).  As  shown  in
Table  3,  there  was  no  signiﬁcant  effect  of  ivabradine  on
w
g
rnfarct  size  at  follow-up  CMR  compared  with  the  control
roup,  whether  expressed  as  an  absolute  value  (P  =  0.48)  or
s  a  percentage  of  LV  mass  (P  =  0.97).
iscussion
his  study  shows  that  ivabradine  improves  LV  remodelling
fter  AMI  when  added  to  current  guideline-based  therapy,
ncluding  beta-blockers,  in  STEMI  patients  treated  with  suc-
essful  PPCI.  The  ivabradine  group  showed  a  signiﬁcant
eduction  in  LVEDV  and  LVESV  indexes  compared  with  the
ontrol  group  after  3  months  (P  =  0.04  and  P  =  0.01,  respec-
ively).  Regarding  LVEF,  there  was  a  signiﬁcant  (P  =  0.04)
rend  toward  greater  improvement  in  the  ivabradine  group.
 signiﬁcant  reduction  in  HR  was  observed  in  ivabradine
roup  at  initial  and  follow-up  CMR  (P  =  0.02  and  P =  0.006,
espectively).  Furthermore  the  use  of  ivabradine  promptly
fter  angioplasty  appeared  to  be  feasible.
To  our  knowledge,  this  study  is  the  ﬁrst  to  evalu-
te  ivabradine  added  to  current  guideline-based  therapy,
ncluding  beta-blockers,  in  STEMI  patients  treated  with  suc-
essful  PPCI.  Thus  far,  only  one  study  using  echocardiography
as  been  performed  in  patients  after  anterior  myocardial
nfarction,  demonstrating  that  the  ivabradine  group  showed
 signiﬁcant  reduction  in  LVEDV  and  LVESV  indexes  compared
ith  the  metoprolol  group  at  2  months  [9].  However,  in  this
andomized  trial,  the  ivabradine  group  were  not  given  beta-
lockers  and  ivabradine  was  delivered  late  after  angioplasty
i.e.  12  hours)  [9]. The  results  of  this  study  suggest  that  the
arly  introduction  of  ivabradine  in  the  context  of  AMI  is  a
romising  therapeutic  strategy.
Clinical  and  experimental  studies  have  revealed  sev-
ral  mechanisms  that  may  explain  the  beneﬁcial  effects
f  ivabradine  on  cardiac  remodelling.  First,  ivabradine
oes  not  have  negative  inotropic  or  lusitropic  effects;
hus  haemodynamic  and  myocardial  contractility  are  not
mpaired  [17,18]. Ivabradine  leads  to  a  decrease  in  HR,
hich  reduces  myocardial  oxygen  demand  and  simulta-hich  allows  increased  coronary  ﬂow  and  myocardial  oxy-
enation.  Second,  Mulder  et  al.  [8]  observed  in  adult
ats  with  AMI  and  congestive  heart  failure  that  ivabradine
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mproves  the  LV  developed  pressure-volume  relationship,
revents  LV  systolic  dysfunction  and  increases  capillary  den-
ity.  In  the  same  way,  Dedkov  et  al.  have  documented  several
ffects  of  ivabradine  in  middle-aged  rats  with  AMI,  includ-
ng  reduced  periarterial  and  interstitial  collagen  content,
ttenuation  of  the  increase  in  end-diastolic  pressure  and
ttenuation  of  the  decrease  in  LVEF  [19].  These  beneﬁcial
ffects  of  ivabradine  after  AMI  have  been  investigated  in
odels  of  permanent  coronary  ligation.  Third,  in  a rabbit
odel  of  ischaemia  reperfusion,  Couvreur  et  al.  observed
hat  ivabradine  reduced  myocardial  stunning  [20].
In  our  study,  the  addition  of  ivabradine  to  the  beta-
locker  induced  a  signiﬁcant  reduction  in  HR  compared  with
he  control  group.  This  difference  increased  with  time  and
ay  be  related  to  a  ‘delayed  effect’  of  the  molecule.  We
lso  noticed  that  the  bisoprolol  dose  did  not  differ  between
oth  groups  at  follow-up  CMR.  We  can  suppose  that  the
ose  of  beta-blocker  could  have  been  increased  in  the  con-
rol  group  during  follow-up,  which  may  have  attenuated  the
esults.  Therefore  we  propose  that  the  magnitude  of  HR
eduction  by  ivabradine,  administered  in  addition  to  beta-
lockers,  rather  than  the  background  beta-blocker  dose,
xplains  partially  the  effects  on  LV  remodelling.  In  the  same
ay,  similar  ﬁndings  have  been  observed  in  the  SHIFT  study
21].  In  a  experimental  study,  Christensen  et  al.  compared
he  effects  of  atenolol  versus  ivabradine  on  myocardial
erfusion,  coronary  reserve,  and  LV  function  after  AMI
n  middle-aged  rats  [22].  They  observed  that  ivabradine
nduced  more  favourable  remodelling  via  greater  LV  hyper-
rophy  and  lower  LVEDV-to-mass  ratio.  In  the  same  way,  in
ur  study,  there  was  a  signiﬁcant  trend  toward  less  reduction
f  LV  mass  index  (P  =  0.02)  in  the  ivabradine  group.  Further-
ore,  the  additional  effect  of  ivabradine  on  LV  remodelling
n  our  study  was  not  explained  by  the  reduction  of  infarct
ize,  which  was  similar  between  both  groups.
In  this  pilot  study,  ivabradine  treatment  appears  to  be
easible  and  well  tolerated  by  the  patients,  except  in  some
ases  of  excessive  bradycardia.  HR  reduction  with  ivabra-
ine  reverses  LV  remodelling  in  patients  with  heart  failure
nd  documented  LV  systolic  dysfunction  (LVEF  ≤  %35)  [7]. In
iew  of  our  preliminary  results,  we  believe  that  this  treat-
ent  should  be  evaluated  in  association  with  beta-blockers
n  STEMI  patients  presenting  with  severe  LV  dysfunction  and
igh  HR.
This  pilot  study  showed  that  ivabradine  was  associated
ith  a  moderate  reduction  in  LV  volumes  and  increase  in
VEF  compared  with  standard  therapy.  However,  further
arger  trials  are  required  to  determine  whether  a  rather
mall  reduction  in  LV  volumes  with  ivabradine  added  to
tandard  care  translates  into  beneﬁt  in  terms  of  clinical
utcomes.  Adverse  LV  remodelling  occurred  in  14  (21.8%)
atients  in  the  ivabradine  group  and  20  (31.3%)  patients
n  the  control  group  (P  =  0.23).  Given  these  results,  the
ample  size  necessary  for  a  randomized  placebo-controlled
rial  to  demonstrate  a  signiﬁcant  difference  between  both
roups  in  adverse  LV  remodelling  using  the  chi-square  test
an  be  computed  using  PASS  software.  If  the  cut-off  value
or  adverse  LV  remodelling  is  15%  (yielding  a  size  effect  of
.1085),  the  total  sample  size  should  be  894  patients.  Thus,
any  studies  [7]  have  clearly  demonstrated  an  improve-
ent  in  haemodynamics,  LV  remodelling  and  mortality
ith  angiotensin-converting  enzyme  inhibitor  treatment.E.  Gerbaud  et  al.
urthermore,  the  EPHESUS  study  [4]  of  over  6600  patients
ith  AMI  complicated  by  evidence  of  systolic  LV  dysfunction
LVEF  ≤  40%)  showed  that  selective  aldosterone  blockade
ith  eplerenone  resulted  in  15%  reduction  in  total  mortal-
ty.  In  the  same  way,  Hayashi  et  al.  [23]  showed  that  MRA
pironolactone  combined  with  an  angiotensin-converting
nzyme  inhibitor  can  prevent  postinfarct  LV  remodelling  in
ssociation  with  the  suppression  of  a  marker  of  collagen
ynthesis.
This  study  is  not  a  randomized  trial.  However,  we  chose
 non-randomized  observational  study  design  to  evalu-
te  the  advantages  and  disadvantages  of  ivabradine  in
 possible  new  indication  (i.e.  its  effectiveness  in  STEMI
atients  treated  with  successful  PPCI).  Thus,  larger  random-
zed  double-blind  multicentre  studies,  including  particularly
atients  with  unsuccessful  reperfusion  (TIMI  ﬂow  grade  ≤  2),
re  required.  Moreover,  a  longer  follow-up  period  of  6
onths  or  1  year  would  provide  additional  interesting  data.
inally,  postconditioning,  which  reduces  infarct  size  by
0—40%  with  a  signiﬁcant  improvement  in  contractile  func-
ion  continuing  1  year  after  AMI  [24], was  not  performed  in
his  study.
onclusions
e  observed  in  this  pilot  study  that  in  TIMI  3  reperfused
TEMI,  the  early  administration  of  ivabradine  may  improve
V  remodelling  when  added  to  current  guideline-based  ther-
py,  including  beta-blockers.  Given  these  promising  results,
arger  randomized  studies  are  necessary  to  conﬁrm  our  ﬁnd-
ngs.
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